What Has Been the Growth of the Retinal Vein Occlusion Treatment Market So Far?
The retinal vein occlusion treatment market has seen considerable growth due to a variety of factors.
• The retinal vein occlusion treatment market has seen strong growth in recent years. It will increase from $2.26 billion in 2024 to $2.43 billion in 2025, at a compound annual growth rate (CAGR) of 7.3%.
The growth can be attributed to the adoption of combination therapies targeting multiple disease aspects, the increasing prevalence of diabetes and hypertension, greater access to specialized care, clinical trials validating new treatments, and advancements in anti-VEGF therapies.
How Will the Retinal Vein Occlusion Treatment Market?
The retinal vein occlusion treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The retinal vein occlusion treatment market is expected to grow to $3.18 billion by 2029, with a compound annual growth rate (CAGR) of 7.0%.
This growth is driven by factors such as cost-effectiveness, reimbursement policies, patient preferences for non-invasive treatments, rising global healthcare spending, an aging population, and the development of new therapies. Key trends include advancements in gene therapy, nanotechnology for drug delivery, AI in diagnostics, telemedicine, and patient-centric technologies.
Which Factors Are Boosting Growth In The Retinal Vein Occlusion Treatment Market?
The surge in eye-related problems is anticipated to drive advancements in the retinal vein occlusion treatment market. When we talk about eye conditions, we refer to any ailment or disorder that affects eye health or vision, ranging from minor irritations and infections to severe issues such as glaucoma, cataracts, macular degeneration, and diabetic retinopathy. The spike in eye-related ailments can be credited to factors like an aging demographic and a rise in diabetes and hypertension cases. The objective of retinal vein occlusion treatment is to re-establish blood circulation and alleviate inflammation to avert loss of sight and manage any complications arising from this eye condition. For instance, the Centers for Disease Control and Prevention, a US-based science and data-driven health protection organization, reported that over 3.4 million Americans 40 years or older were blind or had visual impairment in January 2024, a number that is predicted to double by 2030. Consequently, the upsurge in eye-related conditions is fueling the expansion of the retinal vein occlusion treatment market.
What Key Areas Define The Segmentation Of The Global Retinal Vein Occlusion Treatment Market?
The retinal vein occlusion treatment market covered in this report is segmented –
1) By Disease Type: Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)
2) By Diagnosis: Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography
3) By Treatment: Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Other Treatments
4) By End-User: Hospital And Clinics, Research And Academics, Other End-Users
Subsegments:
1) By Central Retinal Vein Occlusion (CRVO): Non-Ischemic CRVO, Ischemic CRVO
2) By Branch Retinal Vein Occlusion (BRVO): Non-Ischemic BRVO, Ischemic BRVO
Pre-Book The Retinal Vein Occlusion Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Retinal Vein Occlusion Treatment Industry?
Key players in the market for retinal vein occlusion treatment are directing their efforts towards the creation of novel products, like interchangeable biosimilars, to broaden treatment possibilities and increase accessibility for patients. Interchangeable biosimilars are biologic medications that mirror existing biologics very closely, providing an efficient alternative for tracking inflammation and fluid leakage. For instance, Biocon Biologics Limited, a firm based in India that specializes in biosimilar production, received approval from the US Food and Drug Administration in May 2024 for Yesafili (aflibercept-jbvf), an interchangeable biosimilar for EYLEA (aflibercept). This product, acting as a vascular endothelial growth factor (VEGF) inhibitor, is utilized in the treatment of several eye-related conditions such as neovascular age-related macular degeneration (wet AMD), macular edema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (myopic CNV).
Who Are the Key Players In The Retinal Vein Occlusion Treatment Market?
Major companies operating in the retinal vein occlusion treatment market are:
• Roche Holding AG
• Bayer AG
• Novartis International AG
• Regeneron Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co. Ltd.
• Chengdu Kanghong Pharmaceutical Group Co. Ltd.
• Spark Therapeutics Inc.
• Genentech Inc.
• Apellis Pharmaceuticals Inc.
• Alimera Sciences Inc.
• Ocular Therapeutix Inc.
• EyePoint Pharmaceuticals Inc.
• Aerpio Pharmaceuticals Inc.
• REGENXBIO Inc.
• Stealth BioTherapeutics Corp.
• Adverum Biotechnologies Inc.
• Graybug Vision Inc.
• Oxurion NV
• PanOptica Inc.
• Clearside Biomedical Inc.
What Is The Most Dominant Region In The Retinal Vein Occlusion Treatment Market?
North America was the largest region in the retinal vein occlusion treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
